CPRX EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
CPRX's ev/ebitda is lower than 65% of the last 10 years.
EV/EBITDA History
CPRX EV/EBITDA by year
Yearly range of CPRX’s ev/ebitda from 2019 to 2026. Over the full period it ranged from 4.8 to 63.0, averaging 12.2.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 7.0 | 8.4 | 9.7 | 9.7 |
| 2025 | 6.0 | 8.4 | 12.2 | 7.5 |
| 2024 | 9.5 | 13.6 | 18.7 | 9.5 |
| 2023 | 7.4 | 12.0 | 19.9 | 16.3 |
| 2022 | 7.7 | 13.6 | 22.9 | 21.7 |
| 2021 | 5.7 | 9.8 | 13.5 | 10.8 |
| 2020 | 4.8 | 8.0 | 14.5 | 5.4 |
| 2019 | 9.7 | 50.5 | 63.0 | 9.7 |
Get notified when CPRX EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is CPRX EV/EBITDA High or Low Right Now?
Catalyst Pharmaceuticals, Inc.'s EV/EBITDA is currently 9.7, which is below average relative to its 10-year historical range. The 10-year median EV/EBITDA for CPRX is approximately 10.3. See all CPRX valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.